1-(2-cyclobutylphenyl)ethanone | 936249-91-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-cyclobutylphenyl)ethanone
• 英文别名: 1-(2-Cyclobutylphenyl)ethan-1-one
• CAS: 936249-91-1
• 化学式: C₁₂H₁₄O
• 分子量: 174.243
• InChiKey: AEBUBWRTHXLFSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  环丁基溴 、 N-(4-methoxyphenyl)-1-phenylethanimine 在 neopentylmagnesium bromide 、 cobalt(II) bromide 、 1,3-diisopropyl-1H-benzo[d]imidazol-3-ium bromide 、 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以75%的产率得到1-(2-cyclobutylphenyl)ethanone
  参考文献：
  名称：

  钴催化芳族亚胺与伯和仲烷基卤化物的邻位烷基化

  摘要：

  我们在这里报告了钴-N-杂环卡宾催化系统，用于芳族亚胺与烷基氯化物和溴化物的邻位烷基化，它允许在室温下引入各种伯和仲烷基。仲烷基卤化物反应的立体化学结果表明，本反应涉及从钴物种到烷基卤化物的单电子转移以生成相应的烷基自由基。通过该方法获得的环烷基化产物可以通过操纵导向和环烷基转化为独特的螺环。

  DOI：

  10.1021/ja403759x

文献信息

• Cobalt-Catalyzed Chelation-Assisted Alkylation of Arenes with Primary and Secondary Alkyl Halides
  作者：Naohiko Yoshikai、Ke Gao、Takeshi Yamakawa

  DOI：10.1055/s-0033-1338658

  日期：——

  center to the alkyl halide to form the corresponding alkyl radical, which has a finite lifetime before it undergoes C–C bond formation. Cobalt–N-heterocyclic carbene catalytic systems have been developed for chelation-assisted ortho-alkylation of aromatic compounds with alkyl halides. Aryl imines can be selectively monoalkylated at room temperature by various primary or secondary alkyl chlorides or

  摘要 已经开发了钴-N-杂环卡宾催化体系，用于将芳族化合物与烷基卤化物进行螯合辅助的正烷基化。芳亚胺可以在室温下被各种伯或仲烷基氯化物或溴化物选择性地单烷基化。该催化体系也可以应用于2-芳基吡啶衍生物，其在不存在位阻的情况下可以通过过量的烷基卤来进行二烷基化。包括立体化学探针和自由基钟的反应在内的机械实验表明，该反应涉及从钴中心到卤代烷的单电子转移，从而形成相应的烷基，在经历C–C键形成之前，其寿命有限。 已经开发了钴-N-杂环卡宾催化体系，用于将芳族化合物与烷基卤化物进行螯合辅助的正烷基化。芳亚胺可以在室温下被各种伯或仲烷基氯化物或溴化物选择性地单烷基化。该催化体系也可以应用于2-芳基吡啶衍生物，其在不存在位阻的情况下可以通过过量的烷基卤来进行二烷基化。包括立体化学探针和自由基钟的反应在内的机械实验表明，该反应涉及从钴中心到卤代烷的单电子转移，从而形成相应的烷基，在经历C–C键形成之前，其寿命有限。
• 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS
  申请人：KUDUK Scott D.

  公开号：US20160102073A1

  公开（公告）日：2016-04-14

  The present invention is directed to 2-hydroxymethyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-羟甲基化合物，它们是促进睡眠的药物受体拮抗剂。本发明还涉及上述化合物在潜在的神经和精神障碍和疾病的治疗或预防中的用途，其中促进睡眠的药物受体参与其中。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗促进睡眠的药物受体参与的疾病中的用途。
• 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS
  申请人：Kim Ronald M.

  公开号：US20170320874A1

  公开（公告）日：2017-11-09

  The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
• [EN] 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES OCTAHYDROPYRROLOPYRIDINES 6,5-BICYCLIQUES DU RÉCEPTEUR D'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016100157A2

  公开（公告）日：2016-06-23

  The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.